WHITEHOUSE STATION, N.J., Aug. 26, 2011 – Merck, known as MSD outside the United States and Canada, said today that the Texas Supreme Court overturned a judgment in favor of the family of Leonel Garza Sr. in a suit alleging that VIOXX caused Mr. Garza’s death. 

The San Antonio Court of Appeals had previously overturned the verdict due to jury misconduct and ordered a new trial.  The Texas Supreme Court found that the evidence did not support the plaintiffs therefore ordered final judgment in favor of Merck.

In today’s opinion, Justice Nathan L. Hecht wrote for the court: "we . . . hold that the Garzas did not present reliable evidence of general causation and are therefore not entitled to recover against Merck."   

“Today's decision reaffirms that there is simply no reliable scientific evidence that VIOXX caused the plaintiff's heart attack,” said Ted Mayer of Hughes Hubbard & Reed, outside counsel for Merck.

The Texas Court of Appeals had reversed the jury's verdict and ordered a retrial.  The jury's original verdict on April 21, 2006 included $7 million in compensatory damages and $25 million in punitive damages.  On Dec. 21, 2006, the punitive award was reduced to $750,000 in compliance with Texas statutory caps.

During the trial, Merck was represented by Richard L. Josephson and Travis J. Sales of Baker Botts L.L.P., Houston, Texas.  Merck's lead appellate counsel is Baker Botts partner Stephen G. Tipps.

On Nov. 9, 2007, Merck announced that it had entered into an agreement to resolve myocardial infarction and stroke claims filed as of that date in the United States.  The $4.85 billion program established by the agreement resolved more than 99.9 percent of eligible claims in the United States.  The Garza case was excluded from the program.

About Merck

Today's Merck is a global healthcare leader working to help the world be well.  Merck is known as MSD outside the United States and Canada.  Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.  We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.  For more information, visit

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.  Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts.  Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties.  Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2010 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (